Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1Phase 2/3 1

Status

Recruiting 25Unknown 15Not yet recruiting 9Terminated 5Active not recruiting 5Completed 3Withdrawn 2

Sponsor Class

OTHER 5INDUSTRY 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 629Prostatic Neoplasms 372Neoplasms 304Carcinoma, Non-Small-Cell Lung 216Lung Neoplasms 205Colorectal Neoplasms 176Multiple Myeloma 143Pancreatic Neoplasms 135Leukemia, Myeloid, Acute 129Neoplasm Metastasis 124Melanoma 116Brain Neoplasms 116Ovarian Neoplasms 101Carcinoma, Hepatocellular 101Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Glioblastoma 99Uterine Cervical Neoplasms 97Head and Neck Neoplasms 95Squamous Cell Carcinoma of Head and Neck 93Colonic Neoplasms 82Stomach Neoplasms 81Recurrence 80Rectal Neoplasms 80Urinary Bladder Neoplasms 77Sarcoma 77Triple Negative Breast Neoplasms 75Carcinoma, Renal Cell 75Lymphoma 71Lymphoma, Non-Hodgkin 67Myelodysplastic Syndromes 66

Interventions

Trastuzumab 3pertuzumab 2Paclitaxel 2pegfilgrastim 1atezolizumab 1Docetaxel 1Carboplatin 1ARX788 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × HER2-positive Breast Cancer × Clear all
NCT03125928 2026-05-22

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Fox Chase Cancer Center

Phase 2 Active not recruiting
16 enrolled
Breast

HER2-positive Breast Cancer

NCT05705401 2026-04-27

HERO

NRG Oncology

Phase 3 Active not recruiting
1,300 enrolled
Breast

HER2-positive Breast Cancer

NCT03571633 2025-11-26

BREASTIMMU02

Centre Leon Berard

Phase 2 Active not recruiting
90 enrolled
Breast

HER2-positive Breast Cancer

NCT03460067 2025-03-27

Omission of Radiation in Patients With Her-2 Positive Breast Cancer

University of Kansas Medical Center

Phase NA Active not recruiting
12 enrolled
Breast

HER2-positive Breast Cancer

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Shengjing Hospital

Phase 2/3 Active not recruiting
136 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡